Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07273773 · ClinicalTrials.gov registry record · NA
Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction
A NA study of Erectile Dysfunction (ED), sponsored by Rigicon.
- Recruiting
- Registry status
- NA
- Development phase
- 182
- Enrollment target
- 7
- Study locations
NCT07273773: Recruiting NA study of Erectile Dysfunction (ED), sponsored by Rigicon.
NCT07273773 is a NA study of Erectile Dysfunction (ED) that is actively recruiting participants, run by Rigicon. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07273773, a NA study of Erectile Dysfunction (ED), is actively recruiting participants, sponsored by Rigicon.
- RECRUITING
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.
Primary Outcome
Success will be concluded if the two-sided 95 percent confidence interval (equivalently, one-sided 97.5 percent) for the 12-month proportion has its lower bound strictly greater than 0.90 as specified in the statistical plan.
Conditions Studied
Interventions
- DEVICE Rigicon Infla10® Inflatable Penile Prosthesis (IPP)
Study Locations (7)
Texas
- Urology Partners of North Texas - Arlington
- Vitality Urology Institute - Houston
Florida
- Perito Urology - Coral Gables
Georgia
- Atlanta Cosmetic Urology - Atlanta
Illinois
- UroPartners - Chicago
Massachusetts
- Kramer Urology - Hyannis
New York
- Washington Heights Urology - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2029-07 |
| Phase | NA |
What NCT07273773 shows while recruiting
NCT07273773 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Erectile Dysfunction (ED) appearing as the primary indexed condition, and to 1 intervention - of which Rigicon Infla10® Inflatable Penile Prosthesis (IPP) is the first listed.
NCT07273773 lists 7 locations in 6 states (Texas, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT07273773 about?
NCT07273773 is a clinical study titled "Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction". This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.
What is the current status of trial NCT07273773?
This trial is currently recruiting. It is a NA study. The enrollment target is 182 participants. The study started on 2026-01-26. Estimated completion is 2029-07.
What conditions does trial NCT07273773 study?
This clinical trial studies the following conditions: Erectile Dysfunction (ED).
What interventions are being tested in trial NCT07273773?
The interventions under investigation include: Rigicon Infla10® Inflatable Penile Prosthesis (IPP) (DEVICE).
Who is sponsoring clinical trial NCT07273773?
This trial is sponsored by Rigicon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07273773 being conducted?
This trial has 7 study locations across Florida, Georgia, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07273773's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI